Clinical importance of proteinuria in Diabetes Mellitus
DOI:
https://doi.org/10.51481/amc.v43i2.51Keywords:
Diabetes Mellitus, Nefropatía Diabética, Albuminuria, Insuficiencia RenalAbstract
Background: Due to the growing incidence of Diabetes Mellitus in a younger population, and in view of the poor level of metabolic control reached worldwide for this illness, it is necessary to find simple and practical methods, within our reach, in order to detect the appearance of the chronic complications of Diabetes in very early stages to avoid or at least slow down the natural evolution of them.Aim: To review the most recent evidence of the utility and readiness of different methods to evaluate albuminuria, in order to improve the approach of the diabetic patient, with or without nephropathy.Methodology: Bibliographical review of publications of the last 10 years.
Downloads
References
Winocour Ph. Microalbuminuria. BMJ 1992, 304: 1196-7.
Jarret RJ, Viberti GC, Argyropulus A, Hill RD, Mahmud U, Murrells TJ. Microalbuminuria predicts mortality in non- Insulin-Dependent Dia-betes. Diabetes Med 1984,1:17-19.
Moge nsen CE. Microalbuminuria Predicts Clinical Prote inuria and Early Mortality in Maturity Onset Diabetes. N Engl J Med 1984; 310: 356-60.
Viverti GC, Hill RD, Jarret RJ, Argyropoulus A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical Nephropathy in Insulin- Dependent Diabetes. Lancet 1982; i1430-32.
Mattock MB, Barnes DJ, Viberti JC, Keen H, Burt D, Hughes JM, Fitz-gerald AP. Microalbuminuria and Coronary Heart Disease in NIDDM. Diabetes 1998; 47: 1786-92.
Nauchin MK, Kawano T, Uyama H, Shaiiki H, Dohi K. Discordance between retinopathy and nefropathy in type 2 Diabetes. Nephron 1998; 80:171-74.
Pennoi G, Chaturved N, Tolmud J PhD, Cotroneo P, Manto A, Nanni-pieri M, Loung L, Fuller JH and the EUCLID Study Group. Diabetes 1998; 47: 1507-11.
The EUCLID Study Group. Randomized Placebo-Contr olled trial of Lisinopril in Normote nsive Patients with Insulin-depe ndent Diabetes and Normoalbuminuria or Microalbuminuria. Lancet 1997; 349:1787-92.
Tonolo G, Ciccaresse M, Brizzi P, Puddu L, Zecchi G y cols. Reduc-tion of Albumin Excretion Rate in Normotensive Microalbuminuric type 2 Diabetic Patients During Long-Term Simvastatin Treatment. Diabetes Care. 1997; 20: 1891-95.
Bakris GL, Stein JH. Diabetes Nephropathy. Disease-a-month 1993; 39: 573-612.
Diabetic Nephropathy Position Statement, American Diabetes Associa-tion. Diabetes Care 1999; 22 (1): A66-A69.
Morrison G, Neilson EG, Sheeram A, Alan G, Wassertein SM, Kobonin SM. Diabetic Nephropathy. Disease a Month 1998; 44 (5): 214-34.
Poinier Zuny SJ. New México: Preserving the Diabetic kidney. The Am J of Family Practice 1998; 46: 21-7.
Bennet PH, Haffner S. Kasike BL, Keane WF, Mongensen CE, Parving H. Diabetic Renal Disease Recomendations: Am J of Kidney Diseases 1995; 45:107-112.
Zelmanovitz T, Gross JL, Oliveira J, de Acevedo MJ. Proteinuria is Still Useful For The Screenning and Diagnosis of Overt Diabetic Neph-rophaty. Diabetes Care 1998; 21: 1076-79.
Mogensen C, Viberti GC, Petrein E, Kuter D, Hasslacher Ch, Hoffman W, et al. Multicenter Evaluation of the Micral-Test II. Test Strip and Inmunologic Rapid Test for The Detection of Microalbuminuria. Dia-betes Care 1997; 20: 1642-46.
The Diabetes Control and Complications Trial Research Group. The ef fect of Intensive Treatment of Diabetes on the Development and pro-gession of long-term complications in insulino-dependent Diabetes. N Engl J Med 1993; 329:977-86.
UK Prospective Diabetes Study Group. Intensive Blood Glucose Con-trol with Sulphonylureas or Insulin Compared with conventional treat-ment and risk of complication in patients with type 2 Diabetes (UKPDS 33). Lancet 1998; 352:837-53.
UK Prospective Diabetes Study Group. Effect of intensive Blood Glu-cose control policy with metformin on complication in Type 2 Diabetes (UKPDS 34). Lancet 1998; 352:854-65.
UK Prospective Diabetes Study Group. Tight Blood Presure Control and Risk of Macrovascular and Microvascular complication in Type 2 Diabetes (UKPDS 38). BMJ 1998; 317: 703-12.
UK Prospective Diabetes Study Group. Efficacy of Atenolol and Capto-pril in Reducing. Risk of Macrovascular and Microvascular complica-tion in Type 2 Diabetes (UKPDS 39). BMJ 1998; 317:713-25.
Bangstad H, Osterby R, Hartmann A, Berg TJ, Hanssen KF. Severity of Glomerulopathy predicts Long-Term Urinary Albumin Excretión Rate in Patients With Type 1 Diabetes and Microalbuminuria. Diabetes Care 1999;
: 314-19.
Chaiken RL, Eckert-Norton M, Bard M, Banerji M, Palmisano J, Sachi-mechi I, Levovitz HE. Hiperfiltration in African-American patients with type 2 Diabetes. Diabetes Care 1998; 21: 2129-34.
Ranid M, Brosh D, Ravid-Safran D, Levi Z, Rachmani Z. Main Risk Factores For Nephropathy in type 2 Diabetes Mellitus are plasma Cho-lesterol levels; mean Blood Presure and hyperglycemia. Arch Intern Med 1998; 158: 998-1004.
American Diabetes Association. Consensus Development Conference on the Diagnosis of Coronary Heart Disease in People with Diabetes. Diabetes Care 1998; 21: 1551-55.
Annegall M, Hougaard PhD, Borch- Johnsen K, Parving H. Risk Fac-tor for Development of incipient and overt Diabetes Nephropathy in Patients with non-Insulin Dependent Diabetes Mellitus, Prospective Observational Study. BMJ 1997, 314: 783-88.
Downloads
Published
Issue
Section
License
Copyright (c) 2008 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
